Results 191 to 200 of about 4,700,345 (286)
Posaconazole-induced primary adrenal insufficiency concomitant with pseudoaldosteronism under normal blood pressure. [PDF]
Katsumata M, Miura M, Masuzawa M.
europepmc +1 more source
Compensatory corticosterone‐mediated lipolysis and hepatic gluconeogenesis (via amino acids and glycerol) prevent hypoglycemia in GCGKO mice during prolonged fasting. ABSTRACT Aims/Introduction Glucagon is a key regulator of fasting glucose homeostasis, but the contribution of adrenal hormones during prolonged fasting remains unclear.
Sayumi Kanie +13 more
wiley +1 more source
Autoimmune Primary Adrenal Insufficiency in a Pregnant Patient Without Autoimmune Comorbidities. [PDF]
Reyes NA, McDonald V, Culver SA.
europepmc +1 more source
Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial
In this randomized controlled trial, cumulative isotretinoin doses of 120 and 150 mg/kg showed similar relapse rates at 12 months. Both regimens achieved substantial and comparable reductions in inflammatory acne lesions across the face, chest and back.
Ruggero Cascio Ingurgio +16 more
wiley +1 more source
Mineralocorticoid effects of fludrocortisone and hydrocortisone in primary adrenal insufficiency: EU-AIR patient data. [PDF]
Ekman B +6 more
europepmc +1 more source
Modulation of sebocyte function in acne: A pathway‐inclusive review
Acne is multifactorial, with the sebocyte acting as a central immunometabolic hub linking lipogenic, inflammatory, hormonal and barrier pathways. Mapping established and investigational therapies onto this sebocyte‐centred model offers a mechanism‐based framework that complements existing treatment paradigms and may guide more targeted, antibiotic ...
Christos C. Zouboulis +3 more
wiley +1 more source
Concomitant Immune Checkpoint Inhibitors Induced Central and Primary Adrenal Insufficiency: A Diagnostic Challenge. [PDF]
Nascè A +4 more
europepmc +1 more source
Immune‐related adverse events with mogamulizumab in cutaneous T‐cell lymphoma: A multicentre study
In a nationwide multicentre study of 403 patients with cutaneous T‐cell lymphoma treated with mogamulizumab, non‐MAR immune‐related adverse events were reported in 8.4% of patients across responding centres. These events were diverse, sometimes severe or persistent, and could occur late during mogamulizumab treatment.
David Neubauer +28 more
wiley +1 more source

